Therapy Switches in Fingolimod-Treated Patients with Multiple Sclerosis: Long-Term Experience from the German MS Registry.
Niklas FrahmFiras FneishDavid EllenbergerPeter FlacheneckerFriedemann PaulClemens WarnkeChristoph KleinschnitzTina ParciakDagmar KreftingKerstin HellwigJudith HaasPaulus Stefan RommerAlexander StahmannUwe K ZettlPublished in: Neurology and therapy (2022)
Treatment switches from fingolimod to subsequent DMDs currently occur after shorter treatment durations than 10 years ago, possibly due to the growing treatment spectrum. Planning adequate washout periods is essential and should be done on an individualized basis.